Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACACB | O00763 | 5/20 | 0.45 |
| ▸ | ACACA | Q13085 | 4/20 | 0.45 |
| ▸ | LTA4H | P09960 | 2/20 | 0.44 |
| ▸ | MAPT | P10636 | 3/20 | 0.44 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.43 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.42 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.42 |
| ▸ | MMP12 | P39900 | 1/20 | 0.40 |
| ▸ | MMP13 | P45452 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19944473 | 0.96 | LTA4H (0.47) | ACACBACACALTA4HMAPTMTNR1A | |
| SCHEMBL4197201 | 0.96 | MAPT (0.47) | MAPTMTNR1AMTNR1BSMN1; SMN2POLB | |
| SCHEMBL4197511 | 0.93 | MAPT (0.50) | MAPTMTNR1AMTNR1BSMN1; SMN2LMNA | |
| SCHEMBL4188595 | 0.93 | MAPT (0.50) | MAPTMTNR1AMTNR1BSMN1; SMN2LMNA | |
| SCHEMBL19944372 | 0.90 | MTNR1A (0.50) | MAPTMTNR1AMTNR1BPOLBLMNA | |
| SCHEMBL4184734 | 0.90 | MAPT (0.45) | ACACBACACAMAPTMTNR1AMTNR1B | |
| SCHEMBL4198745 | 0.90 | FFAR4 (0.47) | LTA4HMTNR1AMTNR1BSMN1; SMN2FFAR1 | |
| SCHEMBL4198139 | 0.89 | RXRA (0.49) | MAPTFFAR1FFAR4 | |
| SCHEMBL13383397 | 0.88 | MAPT (0.46) | MAPTSMN1; SMN2POLBLMNA | |
| SCHEMBL4204184 | 0.88 | MAPT (0.46) | MAPTMTNR1AMTNR1BSMN1; SMN2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1627867-B1 | (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF | MITSUI CHEMICALS INC (JP) | 2016-01-20 | — | — | EP | disclosed |
| US-7534909-B2 | (Meth) acrylic ester compound and use thereof | MITSUI CHEMICALS, INC. (JP) | 2009-05-19 | — | — | US | disclosed |
| US-20070078198-A1 | (Meth) acrylic ester compound and use thereof | MITSUI CHEMICALS, INC. (JP) | 2007-04-05 | — | — | US | disclosed |
| EP-1627867-A1 | (METH)ACRYLIC ESTER COMPOUND AND USE THEREOF | Mitsui Chemicals, Inc. (JP) | 2006-02-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070078198-A1 | (Meth) acrylic ester compound and use thereof | METTL14, PAM, TAS2R41 | ACACB 4227/4885ACACA 3147/4885LTA4H 1710/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.